Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response

Haematologica. 2023 Apr 1;108(4):1163-1167. doi: 10.3324/haematol.2022.281954.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antigens, CD19
  • Biological Products* / therapeutic use
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / pathology

Substances

  • axicabtagene ciloleucel
  • Biological Products
  • Antigens, CD19